Sino-Korean Stroke Lipids Expert Forum

Clinical evidence of PCSK9i

Profiles of participating experts

Prof.

Prof.
Haiqing Song (China)

Chief Physician of Xuanwu Hospital, Capital Medical University, Deputy Director of
Neurology.

Secretary-General of neurology branch of China Association for the Promotion of International Exchanges in Healthcare, stroke prevention and control engineering expert of the Brain Prevention Committee of the National Health Commission, chairman of the Pharmacogenic Diseases Committee of the Chinese Pharmacological Society, and chairman of the Stroke Branch of the Beijing Association of Integrative Traditional and Western Medicine
.

Member of the editorial board of the Journal of Cerebrovascular Disease, editorial board member of the Chinese Journal of Cerebrovascular Disease, editorial board member of the Journal of Adverse Drug Reactions, and editorial board member of the Chinese Journal of Cerebrovascular Disease
.

Professor Keun-Sik Hong (Korea)

Professor of Neurology, Inje University, Attending Neurologist, Department of Neurology, IlsanBai Hospital, Inchi University,

Director of the Korean Stroke Society's Guideline Development Committee and Associate Editor
of the Journal of Stroke.

Prof.
Weihai Xu (China)

Professor, doctoral supervisor, chief physician
of the Department of Neurology, Peking Union Medical College Hospital.

He is a member of the Executive Committee of Neurosonics of the World Neurological Union, the chairman of the Neuro ultrasound Committee of the Chinese Medical Doctor Association, the vice chairman of the Neuroscience Committee of the Chinese Research Hospital Association, the vice chairman of the Translational Medicine Branch of the Chinese Stroke Society, the deputy editor-in-chief of Annals of Translational Medicine, and the deputy editor-in-chief
of BMC Neurology.

Professor Jong-sung KIM (Korea)

Professor, Stroke Center, Department of Neurology, Asan Medical Center, Professor, Ulsan University School of Medicine,

Founding Editor of journal of Clinical Neurology, editor-in-chief of Stroke magazine,

Editorial Member of the International Journal of Stroke and Associate Editor
of Cerebrovascular Disease.

1.
Lau K K, Chua B J, Ng A, et al.
Low‐Density Lipoprotein Cholesterol and Risk of Recurrent Vascular Events in Chinese Patients With Ischemic Stroke With and Without Significant Atherosclerosis[J ].
Journal of the American Heart Association, 2021, 10(16): e021855.
DOI:10.
1161/JAHA.
121.
021855.

2.
Chung J W, Cha J, Lee M J, et al.
Intensive statin treatment in acute ischaemic stroke patients with intracranial atherosclerosis: a high-resolution magnetic resonance imaging study (STAMINA-MRI study)[J].
Journal of Neurology, Neurosurgery & Psychiatry, 2020, 91(2): 204-211.
DOI: 10.
1136/jnnp-2019-320893.

3.
Masana L, Girona J, Ibarretxe D, et al.
Clinical and pathophysiological evidence supporting the safety of extremely low LDL levels—The zero-LDL hypothesis[J].
Journal of clinical lipidology, 2018, 12(2): 292-299.
e3.
DOI: 10.
1016/j.
jacl.
2017.
12.
018

4.
Scandinavian Simvastatin Survival Study Group.
Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S)[J].
The Lancet, 1994, 344(8934): 1383-1389.
 

5.
Cannon C P, Braunwald E, McCabe C H, et al.
Intensive versus moderate lipid lowering with statins after acute coronary syndromes[J].
New England journal of medicine, 2004, 350(15): 1495-1504.
DOI: 10.
1056/NEJMoa040583.

6.
LaRosa J C, Grundy S M, Waters D D, et al.
Intensive lipid lowering with atorvastatin in patients with stable coronary disease[J].
New England Journal of Medicine, 2005, 352(14): 1425-1435.
DOI: 10.
1056/NEJMoa040583.

7.
Ridker P M, Danielson E, Fonseca F A H, et al.
Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein[J].
New England journal of medicine, 2008, 359(21): 2195-2207.
DOI: 10.
1056/NEJMoa0807646.

8.
Nicholls S J, Puri R, Anderson T, et al.
Effect of Evolocumab on Progression of Coronary Disease in Statin-Treated Patients: The GLAGOV Randomized Clinical Trial.
JAMA, 2016,316(22):2373-2384.
doi:10.
1001/jama.
2016.
16951

9.
Nicholls S J, Kataoka Y, Nissen S E, et al.
Effect of Evolocumab on Coronary Plaque Phenotype and Burden in Statin-Treated Patients Following Myocardial Infarction[J].
JACC: Cardiovascular Imaging, 2022.
DOI: 10.
1016/j.
jcmg.
2022.
03.
002.

10.
Sabatine M S, Giugliano R P, Keech A C, et al.
Evolocumab and clinical outcomes in patients with cardiovascular disease[J].
New England Journal of Medicine, 2017, 376(18): 1713-1722.
DOI: 10.
1056/NEJMoa1615664.

11.
Giugliano R P, Pedersen T R, Saver J L, et al.
Stroke prevention with the PCSK9 (proprotein convertase subtilisin-kexin type 9) inhibitor evolocumab added to statin in high-risk patients with stable atherosclerosis[J].
Stroke, 2020, 51(5): 1546-1554.
DOI: 10.
1161/STROKEAHA.
119.
027759.

12.
Zhao, Z, Du, S, Shen, S, Luo, P, Ding, S, Wang, G, Wang, L.
Comparative efficacy and safety of lipid-lowering agents in patients with hypercholesterolemia: A frequentist network meta-analysis .
Medicine, 98, 2019.
DOI: 10.
1097/MD.
0000000000014400.

13.
Sanz-Cuesta, B.
E.
and Saver, J.
L.
, 2021.
Lipid-Lowering Therapy and Hemorrhagic Stroke Risk: Comparative Meta-Analysis of Statins and PCSK9 Inhibitors.
Stroke, pp.
STROKEAHA-121.
DOI: 10.
1161/STROKEAHA.
121.
034576.

14.
Mach F, Baigent C, Catapano A L, et al.
2019 ESC/EAS Guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk: the Task Force for the management of dyslipidaemias of the European Society of Cardiology (ESC) and European Atherosclerosis Society (EAS)[J].
European heart journal, 2020, 41(1): 111-188.

15.
Stroke Society of China.
Chin J Stroke, 2019; 14:594-9

16.
Kleindorfer D O, Towfighi A, Chaturvedi S, et al.
2021 guideline for the prevention of stroke in patients with stroke and transient ischemic attack: a guideline from the American Heart Association/American Stroke Association[J].
Stroke, 2021, 52(7): e364-e467.
DOI: 10.
1161/STR.
0000000000000375.